Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo

Next Previous
Drug Profile

Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo

Alternative Names: DS 8201; DS 8201a; ENHERTU; Enhertu; fam-trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki; T-DXd

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Company; Medica Scientia Innovation Research; Seagen
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer; Solid tumours
  • Registered Adenocarcinoma
  • Phase III Ovarian cancer
  • Phase II Biliary cancer; Colorectal cancer; Uterine cancer
  • Phase I/II Urogenital cancer

Most Recent Events

  • 15 Jun 2025 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 15 Jun 2025 Daiichi Sankyo plans a phase III trial for Endometrial cancer (First line therapy) (IV), in August 2025 (NCT07022483)
  • 02 Jun 2025 Efficacy and adverse events data from phase III DESTINY-Breast09 trial in Breast cancer released by AstraZeneca

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top